MIT Solve
Over $1 million in prize funding available for winners
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / MIT Solve, an initiative of the Massachusetts Institute of Technology, believes that to achieve a more sustainable and equitable future for all, we need new voices and solutions. Today, it announced the 2024 Global Challenges and the Indigenous Communities Fellowship to find and scale the best.
Solve invites anyone from anywhere in the world to submit a solution to this year's Global Challenges by April 18. Solve is seeking solutions that use technology in innovative and equitable ways to make learning more inclusive, mitigate and adapt to the climate crisis, improve access to quality health care, build peaceful and prosperous economies, and strengthen Indigenous communities.
The selected innovators will form the 2024 Solver Class, pitch their solutions during UN General Assembly Week, and share over $1 million of available funding. Innovators also take part in a nine-month support program that includes capital, leadership, and community support to scale their solutions.
"MIT Solve is on a quest to find the amazing innovators solving the pressing challenges of their communities and the world. And once we select the best, we mobilize the Solve community to help them scale," says Hala Hanna, Executive Director of MIT Solve. "We can't do this without our generous and foresighted supporters."
The funding available for selected Solvers and Fellows includes:
- MIT Solve $10,000 to each Solver and Fellow selected
- The GM Prize (supported by General Motors) for solutions that help create smart, safe, and sustainable communities around the world, selected from the 2024 Global Learning Challenge, the 2024 Global Climate Challenge, and the 2024 Indigenous Communities Fellowship
- The GSR Foundation Prize (supported by GSR Foundation) for solutions that use technology in an innovative way to address pressing issues in their communities, especially solutions that remove barriers to financial inclusion and place a strong emphasis on learning, selected from any 2024 Global Challenge
- Morgridge Family Foundation AI Innovation Prize (supported by Morgridge Family Foundation) for solutions that use AI to boldly spark change through innovation, disruption, and transformation, selected from any 2024 Global Challenge or from any Solver class
- The AI for Humanity Prize (supported by The Patrick J. McGovern Foundation) for solutions that leverage data science, artificial intelligence, and/or machine learning to benefit humanity, selected from any 2024 Global Challenge
- Prince Albert II of Monaco Ocean Innovation Prize (supported by Prince Albert II of Monaco Foundation) for a solution that supports innovation for coasts, oceans, and the broader blue economy, selected from the 2024 Global Climate Challenge
More prizes will be announced. Interested in building a better future by sponsoring a prize or Challenge? Connect at partnerships@solve.mit.edu to talk about catalyzing change through social innovation.
About MIT Solve
Solve is an initiative of MIT. We believe that to achieve a more sustainable and equitable future for all, we need new voices and ideas. We launch open calls for exceptional and diverse solutions to the most pressing global challenges from anyone, anywhere in the world. Selected innovators get the backing of MIT and our community of supporters to scale their impact and drive lasting change. Join us on this mission.
Submit your solution. Support our work. Fund your own challenge.
Media Contact
Maya Bingaman
Officer, Communications & Content
maya.bingaman@solve.mit.edu
SOURCE: MIT Solve
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
